Hims & Hers Health Management
Management criteria checks 3/4
Hims & Hers Health's CEO is Andrew Dudum, appointed in Sep 2016, has a tenure of 9.75 years. total yearly compensation is $22.96M, comprised of 2.2% salary and 97.8% bonuses, including company stock and options. directly owns 7.74% of the company’s shares, worth $501.55M. The average tenure of the management team and the board of directors is 3.5 years and 4.5 years respectively.
Key information
Andrew Dudum
Chief executive officer
US$23.0m
Total compensation
| CEO salary percentage | 2.16% |
| CEO tenure | 9.8yrs |
| CEO ownership | 7.7% |
| Management average tenure | 3.5yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Narrative Update • May 24
HIMS: Renewed GLP 1 Partnership Will Drive Future Cash Pay Opportunity
Analysts have lifted their blended price target on Hims & Hers Health to $26.82 from $24.31, reflecting updated revenue and valuation assumptions following recent research that highlights both higher modeled growth and ongoing margin and GLP-1 transition risks. Analyst Commentary Recent research on Hims & Hers Health shows a wide range of views, with some analysts focusing on new partnerships and product opportunities while others stress margin, regulatory and execution risks.Seeking Alpha • May 17
Hims & Hers Health: GLP-1 Drama Ending Signals Return To Growth
Summary Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consensus, and does not yet reflect the Eucalyptus acquisition. The company faces short-term margin pressure from branded GLP-1 drugs and international scaling, but the long-term target remains at least 20% EBITDA margins in 2030. The stock could approach $4B in 2027 revenues, with Hims valued below $6B and trading at only 1.7x 2027 sales targets of just $3.4B. Read the full article on Seeking Alpha
Narrative Update • May 01
HIMS: Novo Partnership And GLP 1 Pivot Will Support Future Profitability
Analysts have reset their price target framework for Hims & Hers Health to $35.00, incorporating more tempered revenue growth assumptions, a slightly higher discount rate, an improved profit margin outlook, and a lower future P/E multiple informed by recent research citing both the renewed Novo Nordisk partnership and evolving GLP-1 and legal risk views. Analyst Commentary Street research on Hims & Hers Health has shifted meaningfully in recent months, with several firms revising price targets and ratings after the renewed Novo Nordisk partnership, changes in GLP-1 offerings, and evolving views on legal and regulatory risk.
Narrative Update • Apr 30
Hims & Hers Paves the Path to $1 Billion Quarterly Revenue in end of 2026
Recent deal and acquisition news have shed more light on the path to growth.Narrative Update • Apr 17
HIMS: Renewed GLP 1 Partnership Will Face Lingering Regulatory And Execution Risks
The analyst price target for Hims & Hers Health increases slightly to $24.31 from $24.15 as analysts factor in easing peptide restrictions, reduced litigation risk and the renewed Novo Nordisk partnership, along with updated assumptions for future P/E and profitability. Analyst Commentary Recent research on Hims & Hers Health clusters around two themes: renewed optimism tied to the Novo Nordisk partnership and easing peptide restrictions, and lingering concerns around GLP-1 execution, earnings quality, and legal or regulatory risk.Narrative Update • Apr 03
HIMS: Renewed GLP 1 Partnership Will Shape Future Upside Potential
The analyst price target for Hims & Hers Health has moved slightly higher to about $24, as analysts factor in updated views on GLP-1 partnerships, reduced litigation risk, and mixed reactions to recent guidance updates. Analyst Commentary Recent research views on Hims & Hers Health show a wide range of opinions, with some firms lifting targets and ratings on the back of the Novo Nordisk partnership and GLP-1 potential, while others remain cautious after prior guidance updates, litigation concerns, and questions around compounded GLP-1 products.Narrative Update • Mar 20
HIMS: Novo Partnership And Menopause Expansion Will Shape Balanced Future Upside
The updated analyst price target for Hims & Hers Health shifts from about $44 to around $24 as analysts factor in slightly lower assumptions for revenue growth and profit margins, along with a more conservative future P/E multiple, even though there have been recent target raises tied to reduced legal risk and new GLP-1 partnership opportunities. Analyst Commentary Recent Street research around Hims & Hers Health clusters around two themes: the renewed agreement with Novo Nordisk on branded GLP-1s and a reset of expectations after the Q4 report and 2026 guidance.Narrative Update • Mar 07
Review of status after Q4 2025 results
A lot has happened since the last update. This status check is explaining where is Hims and how to reach long term goals.
Narrative Update • Mar 07
FY2025
Updated with most recent annual report.
Narrative Update • Mar 06
HIMS: GLP-1 Regulatory And Legal Pressures Will Limit Future Share Upside
The Analyst Price Target for Hims & Hers Health has been trimmed from $13.00 to $12.50 as analysts factor in recent target cuts tied to regulatory questions around compounded GLP-1s, softer profit expectations, and mixed post earnings commentary across the Street. Analyst Commentary Recent research updates point to a clear reset in expectations for Hims & Hers Health, with multiple firms cutting price targets following the latest Q4 report, guidance, and growing regulatory questions around compounded GLP-1 offerings.Narrative Update • Feb 19
HIMS: Legal And Regulatory Setbacks Will Restrain Future Share Returns
The updated analyst price target for Hims & Hers Health has moved from $25.00 to $13.00, reflecting a broad reset from recent firm cuts as analysts weigh legal risk and adjust their P/E and growth assumptions. Analyst Commentary Recent Street research has largely moved in the same direction, with multiple bearish analysts trimming their targets on Hims & Hers Health by double digit dollar amounts.Analysis Article • Feb 11
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46%
Unfortunately for some shareholders, the Hims & Hers Health, Inc. ( NYSE:HIMS ) share price has dived 46% in the last...Narrative Update • Feb 05
HIMS: Lab Testing Expansion Will Support Weight Loss And Future Profitability
Analysts trimmed their price target on Hims & Hers Health by about US$10.64, citing updated views on fair value, revenue growth, profit margins, and future P/E expectations following recent research. Analyst Commentary Recent research updates on Hims & Hers Health reflect a reset in fair value assumptions, including a lower price target of about US$25 from one firm, along with a closer look at revenue growth trajectories, margin profiles, and future P/E expectations.Narrative Update • Jan 30
Updated perspective to the company future
A different way to look at the future of Hims and Hers - the subscriber countNew Narrative • Jan 27
Hims & Hers Health - Valuation
🩺 Business Overview Key Metrics Total: -3/17 +1 ✅ Projected Operating Margin: 13.90% +1 ✅ Projected 5-Year Revenue CAGR: 13.87% -2 ❌❌ Last 5-Year ROIC: -7.80% -2 ❌❌ Estimated Cost of Capital: 7.76% (greater than ROIC) -1 ❌ Last 5-Year Shares Outstanding CAGR: +2.65% +2 ✅✅ Projected 5-Year EPS CAGR: 23.29% +0 ⚠️ Projected 5-Year Dividend CAGR: N/A +2 ✅✅ Estimated Debt Rating: Aaa -2 ❌❌ Morningstar Moat: None -2 ❌❌ Morningstar Uncertainty: Very High Hims & Hers Health is a high growth company, being currently on a rapid expansion of its business. This has some advantages like the projected stellar growth of both revenue and EPS but it will also normally represent the dillution of shares to support it and the negative ROIC (lower than the cost of capital) that it should be regularized during the next couple of years.Narrative Update • Jan 22
HIMS: GLP-1 Pricing Shifts Will Support Weight Loss And Labs Expansion
Analysts have trimmed their fair value estimate for Hims & Hers Health from US$82.55 to US$74.54, citing lower assumed revenue growth, slightly softer profit margins, and reduced future P/E expectations as competition and GLP-1 pricing changes from TrumpRx, Eli Lilly, and Novo Nordisk reshape the weight loss market. Analyst Commentary Recent research has focused on how GLP-1 pricing changes and the upcoming TrumpRx platform could affect Hims & Hers Health's weight loss offering, particularly its compounded GLP-1 products.Narrative Update • Jan 16
Revised analysis by adding bear scenario to the weight loss.
Market is currently pricing heavy challenges for the weight loss business of Hims and Hers. This is due to: 1) End of Semaglutide shortage, 2) Deal broken with Novo, 3) Warning letter from FDA Therefore added scenario to Hims losing growth in weight loss.
Narrative Update • Jan 14
Revised calculations
More accurate calculations. Made text of the analysis more clear and simple, for easy reading.Narrative Update • Jan 08
HIMS: GLP Pricing And Margin Pressure Will Constrain Future Share Returns
Narrative Update: Hims & Hers Health Analysts have trimmed their blended price target on Hims & Hers Health by about $7 per share, to roughly $59, reflecting cautious views on GLP-1 pricing pressure and margin potential, even as they acknowledge broader growth opportunities such as the new menopause offering and international expansion. Analyst Commentary Recent research on Hims & Hers Health highlights a mix of product expansion and pricing risk, with attention centered on GLP-1 weight loss offerings, the new menopause service, and how these shape the company’s long term margin profile.Analysis Article • Jan 03
Hims & Hers Health (NYSE:HIMS) Seems To Use Debt Rather Sparingly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Dec 23
HIMS: GLP Pricing Pressure Will Challenge Future Margin Expansion
Analysts have trimmed their fair value estimate for Hims & Hers Health from $28.00 to $25.00 per share, reflecting expectations for slower revenue growth, lower margins, a slightly higher discount rate, and increased competitive pressure on GLP-1 pricing that partially offsets the companys broader treatment expansion. Analyst Commentary Recent Street research reflects a more cautious stance on Hims & Hers Health, with several bearish analysts flagging execution and competitive risks that could weigh on the companys valuation.Narrative Update • Dec 09
HIMS: Menopause Expansion Will Drive Future Upside Despite Weight Loss Pricing Headwinds
Analysts have trimmed their average price target on Hims & Hers Health from approximately $46.00 to about $44.36 per share, reflecting expectations for stronger top line growth but slightly lower long term margins as GLP 1 pricing dynamics, competitive pressures and new service investments temper profitability and valuation multiples. Analyst Commentary Bullish analysts highlight that Hims and Hers continues to post solid growth trends despite near term headwinds.Narrative Update • Nov 25
HIMS: Expanding Women's Health and Lab Testing Will Unlock New Market Opportunities
Analysts have trimmed their price target for Hims & Hers Health from $46.67 to $46.00 per share. This reflects increased uncertainty around GLP-1 pricing dynamics and competitive pressures in the direct-to-consumer healthcare market.Analysis Article • Nov 18
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29%
Hims & Hers Health, Inc. ( NYSE:HIMS ) shares have had a horrible month, losing 29% after a relatively good period...Narrative Update • Nov 07
HIMS: Expanding Women's Health Services Will Drive Broader Market Reach
The average analyst price target for Hims & Hers Health has been modestly lowered by approximately $0.75 to $46.67 per share, as analysts trim revenue growth expectations. They also point to intensifying competition and pressure on pricing in the GLP-1 market.Analysis Article • Sep 27
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 33% Share Price Bounce
Hims & Hers Health, Inc. ( NYSE:HIMS ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Sep 19
Telehealth And Hormonal Health Will Transform Global Markets
Hims & Hers Health faces increased regulatory and legal risks, slowing customer growth, and business momentum concerns, prompting analysts to lower their price target from $49.45 to $47.42. Analyst Commentary Increased regulatory headwinds following new FDA reforms for direct-to-consumer advertising, making customer acquisition and marketing more challenging across digital and broadcast platforms.Analysis Article • Jul 22
What You Can Learn From Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S After Its 26% Share Price Crash
Hims & Hers Health, Inc. ( NYSE:HIMS ) shares have retraced a considerable 26% in the last month, reversing a fair...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$13m |
| Dec 31 2025 | US$23m | US$495k | US$128m |
| Sep 30 2025 | n/a | n/a | US$134m |
| Jun 30 2025 | n/a | n/a | US$194m |
| Mar 31 2025 | n/a | n/a | US$164m |
| Dec 31 2024 | US$25m | US$573k | US$126m |
| Sep 30 2024 | n/a | n/a | US$101m |
| Jun 30 2024 | n/a | n/a | US$18m |
| Mar 31 2024 | n/a | n/a | -US$2m |
| Dec 31 2023 | US$14m | US$612k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$36m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$11m | US$600k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$86m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$73m |
| Dec 31 2021 | US$15m | US$574k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$82m |
| Jun 30 2021 | n/a | n/a | -US$72m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$27m | US$527k | -US$18m |
| Sep 30 2020 | n/a | n/a | -US$25m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$58m |
| Dec 31 2019 | US$254k | US$254k | -US$72m |
Compensation vs Market: Andrew's total compensation ($USD22.96M) is above average for companies of similar size in the US market ($USD8.37M).
Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.
CEO
Andrew Dudum (38 yo)
9.8yrs
Tenure
US$22,958,907
Compensation
Mr. Andrew Dudum is Director of Hims & Hers UK Limited since June 11, 2021. Mr. Dudum serves as Chairman of the Board at Hims & Hers Health, Inc. since January 20, 2021 and serves as its Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$22.96m | 7.74% $ 501.6m | |
| Chief Financial Officer | 4.4yrs | US$8.40m | 0.12% $ 7.6m | |
| Chief Operating Officer | less than a year | US$7.73m | 0.18% $ 11.4m | |
| Chief Technology Officer | 1.1yrs | US$60.87m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 5.4yrs | US$4.80m | 0.13% $ 8.4m | |
| Chief Medical Officer & Director | 3.5yrs | US$226.93k | 0.079% $ 5.1m | |
| Chief Policy Officer & Director | less than a year | US$305.93k | 0.012% $ 778.0k | |
| Senior VP | 7yrs | US$961.12k | 0.0038% $ 245.1k | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Chief Communications Officer | less than a year | no data | no data | |
| Senior Vice President of People | no data | no data | no data | |
| Senior Vice President of Men’s Reproductive & Sexual Health | no data | no data | no data |
3.5yrs
Average Tenure
47yo
Average Age
Experienced Management: HIMS's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$22.96m | 7.74% $ 501.6m | |
| Chief Medical Officer & Director | 4.3yrs | US$226.93k | 0.079% $ 5.1m | |
| Chief Policy Officer & Director | 1.6yrs | US$305.93k | 0.012% $ 778.0k | |
| Senior Vice President of Men’s Reproductive & Sexual Health | 4.4yrs | no data | no data | |
| Independent Director | 5.8yrs | US$226.93k | 0.028% $ 1.8m | |
| Lead Independent Director | 5.8yrs | US$274.58k | 0.097% $ 6.3m | |
| Independent Director | 2.3yrs | US$246.08k | 0.056% $ 3.6m | |
| Independent Director | 5.3yrs | US$241.93k | 0.035% $ 2.2m | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | 4.5yrs | no data | no data | |
| Member of Medical Advisory Board | 4.5yrs | no data | no data | |
| Member of Medical Advisory Board | 1.2yrs | no data | no data |
4.5yrs
Average Tenure
57yo
Average Age
Experienced Board: HIMS's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 23:57 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hims & Hers Health, Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Allen Lutz | BofA Global Research |